Who
Peter Greenleaf
Director
Company insider
Files Form 4 as: Director, Pelthos Therapeutics; Chief Executive Officer, Aurinia Pharmaceuticals; Director, Antares Pharma; Director, Biodelivery Sciences International; Chief Executive Officer, Avalo Therapeutics; Director, Kiora Pharmaceuticals; Chief Executive Officer, Sucampo Pharmaceuticals; Director, Savara.
In numbers
- Trades disclosed
- 125
- Buys
- 2
- Sells
- 11
- Bought
- $105K
- Sold
- $7.7M
- Companies
- 10
- Companies where not an officer
- 6
- First trade
- 22 May 2006
- Last trade
- 2 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 6 Oct 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $17K797 at $21.17 | filing |
| 2 Jul 2026filed 7 Jul 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $19K712 at $26.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $2,31885 at $27.27 | filing |
| 2 Jul 2026filed 7 Jul 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $19K712 at $26.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $2,31885 at $27.27 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $8,616420 at $20.52 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $8,053377 at $21.36 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $8,618420 at $20.52 | filing |
| 2 Apr 2026filed 6 Apr 2026 | PTHS Pelthos TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $8,053377 at $21.36 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.4M100,890 at $14.21 | filing |
| 2 Mar 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.4M100,890 at $14.21 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —196,403 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —328,424 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —328,424 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —196,403 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.4M100,171 at $14.40 | filing |
| 20 Feb 2026filed 23 Feb 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.4M100,171 at $14.40 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —165,384 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.8M113,169 at $15.95 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —165,384 at $0.00 | filing |
News
Pelthos Therapeutics (NYSEAMERICAN:PTHS) Downgraded by Zacks Research to Strong SellPTHS · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Peter Greenleaf; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.